JP Morgan Chase
ABUS icon

JP Morgan Chase’s Arbutus Biopharma ABUS Stock Holding History

JP Morgan Chase’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$374K Sell
87,049
-10,826
-11% -$47.3K ﹤0.01% 5184
2025
Q4 		$471K Sell
97,875
-354
-0.4% -$1.59K ﹤0.01% 5091
2025
Q3 		$446K Buy
98,229
+12,152
+14% +$44.6K ﹤0.01% 5101
2025
Q2 		$266K Sell
86,077
-452,552
-84% -$1.5M ﹤0.01% 5094
2025
Q1 		$1.88M Sell
538,629
-357,629
-40% -$1.19M ﹤0.01% 3922
2024
Q4 		$2.93M Buy
896,258
+806,672
+900% +$2.97M ﹤0.01% 3855
2024
Q3 		$345K Buy
89,586
+8,859
+11% +$34K ﹤0.01% 5128
2024
Q2 		$249K Sell
80,727
-7,405
-8% -$22.2K ﹤0.01% 5044
2024
Q1 		$227K Sell
88,132
-27,347
-24% -$70.8K ﹤0.01% 5282
2023
Q4 		$289K Sell
115,479
-3,521
-3% -$6.9K ﹤0.01% 5133
2023
Q3 		$242K Buy
119,000
+13,939
+13% +$29.2K ﹤0.01% 4945
2023
Q2 		$242K Sell
105,061
-189,104
-64% -$492K ﹤0.01% 4963
2023
Q1 		$891K Buy
294,165
+221,321
+304% +$624K ﹤0.01% 4127
2022
Q4 		$170K Buy
72,844
+3,110
+4% +$7.44K ﹤0.01% 5115
2022
Q3 		$133K Buy
69,734
+5,543
+9% +$13K ﹤0.01% 5154
2022
Q2 		$173K Buy
64,191
+5,265
+9% +$13.5K ﹤0.01% 5148
2022
Q1 		$175K Buy
58,926
+16,189
+38% +$49.6K ﹤0.01% 5259
2021
Q4 		$166K Buy
42,737
+5,126
+14% +$19.9K ﹤0.01% 5450
2021
Q3 		$161K Buy
37,611
+2,985
+9% +$9.95K ﹤0.01% 5341
2021
Q2 		$105K Sell
34,626
-486
-1% -$1.5K ﹤0.01% 5522
2021
Q1 		$117K Buy
35,112
+35,076
+97,433% +$135K ﹤0.01% 5333
2020
Q4 		$0 Buy
+36
New +$126 ﹤0.01% 5586
2020
Q3 		– Sell
-33
Closed – – 5437
2020
Q2 		$0 Buy
+33
New +$54 ﹤0.01% 5324
2019
Q4 		– Sell
-95,146
Closed -$145K – 5580
2019
Q3 		$145K Sell
95,146
-209,194
-69% -$360K ﹤0.01% 4763
2019
Q2 		$688K Sell
304,340
-473,130
-61% -$1.21M ﹤0.01% 4067
2019
Q1 		$2.78M Buy
777,470
+765,619
+6,460% +$2.94M ﹤0.01% 3101
2018
Q4 		$46K Sell
11,851
-91,777
-89% -$452K ﹤0.01% 5110
2018
Q3 		$979K Sell
103,628
-113,873
-52% -$1.13M ﹤0.01% 3936
2018
Q2 		$1.59M Sell
217,501
-4,828
-2% -$28.7K ﹤0.01% 3561
2018
Q1 		$1.11M Buy
222,329
+44,531
+25% +$236K ﹤0.01% 3620
2017
Q4 		$898K Buy
177,798
+164,647
+1,252% +$965K ﹤0.01% 3781
2017
Q3 		$84K Buy
13,151
+6,485
+97% +$27.7K ﹤0.01% 4345
2017
Q2 		$24K Sell
6,666
-934
-12% -$3.21K ﹤0.01% 4506
2017
Q1 		$25K Sell
7,600
-2,100
-22% -$5.83K ﹤0.01% 4679
2016
Q4 		$24K Buy
+9,700
New +$28.2K ﹤0.01% 4674
2016
Q3 		– Sell
-1,400
Closed -$6K – 4507
2016
Q2 		$6K Buy
+1,400
New +$5.92K ﹤0.01% 4419
2015
Q3 		– Sell
-21,347
Closed -$253K – 3892
2015
Q2 		$253K Buy
+21,347
New +$325K ﹤0.01% 3760

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

JP Morgan Chase's ABUS Position: Q1 2026 in Review

JP Morgan Chase reduced its Arbutus Biopharma (ABUS) stake by 11% in Q1 2026, selling an estimated $47.3K and leaving 87,049 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #5184.

JP Morgan Chase first reported a position in ABUS in Q2 2015 and has held it in 37 quarters since. The position peaked at $2.93M in Q4 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • JP Morgan Chase held 87,049 shares of Arbutus Biopharma worth $374K as of Q1 2026.
  • JP Morgan Chase sold 10,826 Arbutus Biopharma shares in Q1 2026, an estimated $47.3K.
  • Arbutus Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5184 holding.
  • JP Morgan Chase first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 37 quarters since.
  • JP Morgan Chase's Arbutus Biopharma position peaked at $2.93M in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.